Acadia Healthcare COO resigns; $515k transition payment disclosed

Acadia Healthcare (ACHC) reported leadership changes and furnished quarterly results.

Rhea-AI Filing Summary

Acadia Healthcare (ACHC) reported leadership changes and furnished quarterly results. The company announced that Chief Operating Officer Dr. Nasser Khan resigned effective November 3, 2025. Acadia entered a transition and separation agreement under which Dr. Khan will serve as executive advisor to the CEO through December 31, 2025 and receive a lump-sum payment of $515,000 no later than March 15, 2026. He remains eligible for a 2025 cash bonus based on actual performance as determined by the Board or its Compensation Committee.

Acadia has begun a search for a new COO, with Dr. Khan’s former responsibilities covered by other executive leaders in the interim. The company also furnished a press release with operating and financial results for the third quarter ended September 30, 2025 as an exhibit.

Insights

Healthcare services governance analyst

COO departure with defined transition; Q3 results press release furnished.

Acadia Healthcare disclosed the resignation of its COO, effective November 3, 2025. A formal transition is in place: Dr. Khan continues as executive advisor through December 31, 2025, helping continuity while leadership reallocates duties and begins a COO search.

The agreement includes a lump-sum payment of $515,000 due by March 15, 2026 and eligibility for a 2025 cash bonus subject to actual performance and Board discretion. This sets clear financial terms and preserves performance alignment for the current year.

Operationally, interim coverage by the executive team reduces near-term disruption. The company also furnished Q3 2025 operating and financial results via press release; details are not included here. Subsequent disclosures may provide updates on the COO search and any leadership structure changes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Acadia Healthcare (ACHC) announce regarding its COO?

Dr. Nasser Khan resigned as Chief Operating Officer effective November 3, 2025, with a defined transition period as executive advisor.

How long will Dr. Khan remain with Acadia Healthcare after resigning as COO?

He will serve as an executive advisor to the CEO through December 31, 2025.

What compensation terms were disclosed for Dr. Khan’s transition?

Acadia will pay a lump sum of $515,000 no later than March 15, 2026, and he remains eligible for a 2025 cash bonus based on actual performance.

Who is handling COO responsibilities at Acadia Healthcare during the transition?

Other members of the executive leadership team are assuming the former COO duties on an interim basis.

Did Acadia Healthcare share its third-quarter 2025 results?

Yes. The company furnished a press release with operating and financial results for the quarter ended September 30, 2025 as an exhibit.

Is Acadia Healthcare conducting a search for a new COO?

Yes. The company has initiated a search for a new Chief Operating Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 04:11 PM Learn about SEC filing dates

false 0001520697 0001520697 2025-10-30 2025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 5, 2025 (October 30, 2025)

Acadia Healthcare Company, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-35331		45-2492228
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6100 Tower Circle, Suite 1000 Franklin, Tennessee (Address of Principal Executive Offices) 37067 (Zip Code)

(615) 861-6000

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		ACHC		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company         ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                                         ☐

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2025, Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) issued a press release announcing, among other things, Acadia’s operating and financial results for the third quarter ended September 30, 2025. The press release is furnished herewith as Exhibit 99 hereto and is incorporated herein by reference.

Item 5.02          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 30, 2025, Dr. Nasser Khan notified the Company of his resignation as Chief Operating Officer (“COO”) of the Company, effective November 3, 2025. In connection with his resignation as COO, the Company entered into a transition and separation agreement (the “Khan Transition and Separation Agreement”) with Dr. Khan. Pursuant to the Khan Transition and Separation Agreement, Dr. Khan will be employed as an executive advisor to the Company’s Chief Executive Officer through December 31, 2025, and shall receive a lump-sum payment of $515,000 no later than March 15, 2026. In addition, Dr. Khan will remain eligible to earn a cash bonus for the 2025 performance year, determined based on actual performance achievement, as determined by the Board or the Compensation Committee in its sole discretion.

The Company has initiated a search for a new COO and, in the interim, Dr. Khan’s former COO duties are being assumed by other members of the Company’s executive leadership team.

The foregoing description of the Khan Transition and Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Khan Transition and Separation Agreement, a copy of which is attached hereto as Exhibit 10 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

10 Transition and Separation Agreement, dated October 31, 2025, between Acadia Management Company, Inc. and Dr. Nasser Khan

99 Press Release of Acadia Healthcare Company, Inc., dated November 5, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 5, 2025	ACADIA HEALTHCARE COMPANY, INC.
	By:	/s/ Brian P. Farley
		Brian P. Farley
		Executive Vice President, Secretary and General Counsel